New MRD Assessment Data Using clonoSEQ® To Be Presented at 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

Read More

Browse our 650+ Publications​

Latest Publications

Fixed-Duration Pirtobrutinib plus Venetoclax with or without Rituximab inRelapsed/Refractory CLL: Phase 1b BRUIN Trial

Roeker L, et al.
Blood
June 2024
Authors and Affiliates
Lindsey E. Roeker1, Jennifer A. Woyach2, Chan Y. Cheah3, Catherine C. Coombs4, Nirav N. Shah5, William G. Wierda6, Manish R. Patel7, Nicole Lamanna8, Donald E. Tsai9, Binoj Nair9, Chunxiao Wang10, Xiang Zhao9, Dan Liu10, David Radtke10, Sonya Chapman10, Narasimha Marella9, Samuel C. McNeely9, Jennifer R. Brown11 1Memorial Sloan Kettering Cancer Center, New York, NY, USA 2The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA 3Linear Clinical Research, and Sir Charles Gairdner Hospital, and the University of Western Australia, Perth, Australia 4University of California, Irvine, Orange, CA, USA 5Medical College of Wisconsin, Milwaukee, WI, USA 6MD Anderson Cancer Center, Houston, TX, USA 7Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA 8Columbia University Medical Center/New York-Presbyterian, New York, NY, USA 9Loxo@Lilly, Indianapolis, IN, USA 10Eli Lilly and Company, Indianapolis, IN, USA 11Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Facon T, et al.
New England Journal of Medicine
June 2024
Authors and Affiliates
Thierry Facon, M.D., Meletios‑Athanasios Dimopoulos, M.D., Xavier P. Leleu, M.D., Meral Beksac, M.D., Ludek Pour, M.D., Roman Hájek, M.D., Zhuogang Liu, M.D., Jiri Minarik, M.D., Philippe Moreau, M.D., Joanna Romejko‑Jarosinska, M.D., Ivan Spicka, M.D., Vladimir I. Vorobyev, M.D., Britta Besemer, M.D., Tadao Ishida, M.D., Wojciech Janowski, M.D., Sevgi Kalayoglu‑Besisik, M.D., Gurdeep Parmar, M.D., Pawel Robak, M.D., Elena Zamagni, M.D., Hartmut Goldschmidt, M.D., Thomas G. Martin, M.D., Salomon Manier, M.D., Mohamad Mohty, M.D., Corina Oprea, M.D., Marie‑France Brégeault, M.D., Sandrine Macé, Ph.D., Christelle Berthou, M.S., David Bregman, M.D., Zandra Klippel, M.D., and Robert Z. Orlowski, M.D., for the IMROZ Study Group Department of Hematology, Centre Hospitalier Universitaire (CHU) de Lille, University of Lille, Lille (T.F., S. Manier), the French National Academy of Medicine (T.F.), and the Department of Hematology, Hôpital Saint-Antoine, Sorbonne University and INSERM (M.M.), Paris, Service d’Hématologie et Thérapie Cellulaire, CHU and Centre d’Investigation Clinique INSERM Unité 1402, Poitiers (X.P.L.), the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.), and Sanofi, Research and Development, Vitry-sur-Seine (C.O., M.-F.B., S. Macé, C.B.) — all in France; the Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens (M.-A.D.); the Department of Hematology, Ankara University, and the Istinye University Ankara Liv Hospital, Ankara (M.B.), and the Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul (S.K.-B.) — all in Turkey; the Department of Internal Medicine, Hematology, and Oncology, University Hospital Brno, Brno (L.P.), the Department of Hemato-Oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava, Ostrava (R.H.), the Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Olomouc (J.M.), and the Charles University and General Hospital in Prague, Prague (I.S.) — all in the Czech Republic; Shengjing Hospital of China Medical University, Shenyang, China (Z.L.); the Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw (J.R.-J.), and the Department of General Hematology, Copernicus Memorial Hospital, Comprehensive Cancer Center and Traumatology, Łódź (P.R.) — both in Poland; the S.P. Botkin Moscow City Clinical Hospital, Moscow (V.I.V.); the Department of Hematology, Oncology, Immunology, and Rheumatology, University Hospital of Tübingen, Tübingen (B.B.), and the Department of Internal Medicine V, University of Heidelberg, Heidelberg (H.G.) — both in Germany; the Japanese Red Cross Medical Center, Tokyo (T.I.); Calvary Mater Newcastle, Newcastle, NSW (W.J.), and the Illawarra Cancer Care Centre, Wollongong, NSW (G.P.) — both in Australia; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli,” and Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy (E.Z.); the Division of Hematology–Oncology, University of California, San Francisco, San Francisco (T.G.M.); Sanofi, Patient Safety and Pharmacovigilance, Bridgewater, NJ (D.B.); Sanofi, Cambridge, MA (Z.K.); and the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.).

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Leleu X, et al.
Nature Medicine
June 2024
Authors and Affiliates
Xavier Leleu 1,54 , Cyrille Hulin2,54, Jerome Lambert3, Arthur Bobin1, Aurore Perrot 4, Lionel Karlin5, Murielle Roussel6, Lydia Montes7, Brieuc Cherel8, Thomas Chalopin9, Borhane Slama10, Marie-Lorraine Chretien11, Kamel Laribi12, Claire Dingremont13, Christophe Roul14, Clara Mariette15, Sophie Rigaudeau16, Claire Calmettes17, Mamoun Dib18, Mourad Tiab19, Laure Vincent20, Jacques Delaunay21, Alberto Santagostino22, Margaret Macro23, Emmanuelle Bourgeois24, Frederique Orsini-Piocelle25, Julie Gay26, Benoit Bareau27, Noemie Bigot3, François Vergez28, Pierre Lebreton29, Reza Tabrizi30, Agathe Waultier-Rascalou31, Laurent Frenzel32, Ronan Le Calloch33, Emilie Chalayer34, Thorsten Braun35, Florence Lachenal36, Selim Corm37, Celine Kennel38, Rakiba Belkhir39, Jean-Sebastien Bladé40, Bertrand Joly41, Valentine Richez-Olivier42, Helene Gardeney1, Helene Demarquette43, Daniela Robu-Cretu44, Laurent Garderet45, Muriel Newinger-Porte46, Amine Kasmi47, Bruno Royer48, Olivier Decaux49, Bertrand Arnulf48, Karim Belhadj50, Cyrille Touzeau51, Mohamad Mohty52, Salomon Manier53, Philippe Moreau51, Hervé Avet-Loiseau28, Jill Corre 28 & Thierry Facon53 1Hematology, CIC 1082, U1313, CHU, University, Poitiers, France. 2CHU, Bordeaux, France. 3SBIM, Saint-Louis Hospital, Paris, France. 4University Hospital, iUCT Oncopole, Toulouse, France. 5Hôpital Lyon Sud, Pierre-Benite, France. 6Hematology, CHU, Limoges, France. 7Hematology, CHU, Amiens, France. 8CH Bretagne Atlantique, Vannes, France. 9Hematology, CHU, Tours, France. 10Hospital center, Avignon, France. 11Hematology, University Hospital, Inserm U1231, University of Burgundy Franche-Comté, Dijon, France. 12Hematology, CH, Le Mans, France. 13Internal Medicine, Tarbes-Lourdes Hospital, Tarbes, France. 14CH La Rochelle, La Rochelle, France. 15Hematology, CHU, Grenoble, France. 16Hématologie – Le Chesnay, CH Versaille, Paris, France. 17CH, Périgueux, France. 18University Hospital, Angers, France. 19Hematology, CH Departemental de La Roche-sur-Yon, La Roche-sur-Yon, France. 20CHU, Montpellier, France. 21Hôpital privé du confluent 2, Nantes, France. 22Hematology, CH, Troyes, France. 23Hematology, IHBN – CHU, Caen, France. 24GHICL, Lille, France. 25Hématologie, CH, Annecy Genevois, France. 26Hematology, CH de la côte basque, Bayonne, France. 27Hematology, Les Hôpitaux Privés Rennais Cesson Sévigné - Vivalto Santé, Cesson Sévigné, France. 28Unit for Genomics in Myeloma, iUCT Oncopole, Toulouse, France. 29Hematology, CH, Le Havre, France. 30Hematology, CHI de Mont De Marsan, Mont-de-Marsan, France. 31Hematology, CHU, Nîmes, France. 32Hematology, Necker Hospital, Paris, France. 33Hematology, CH de Cornouaille, Quimper Concarneau, Concarneau, France. 34Hematology, CHU, Saint-Etienne, France. 35Hematology, Avicenne hospital APHP, Bobigny, France. 36CH Pierre Oudot, Bourgoin-Jallieu, France. 37Medipole de Savoie, Challes les Eaux, France. 38CH William Morey, Chalon sur Saône, France. 39Rheumatology, Hopital Bicetre, AP-HP, Universite Paris Saclay, Paris, France. 40Onco-Hematology Department, HIA Sainte Anne, Toulon, France. 41CH Sud Francilien, Corbeil Essonnes, France. 42CHU de Nice, Nice, France. 43Hematology, CH, Dunkerque, France. 44Hematology, CH, Lens, France. 45Hopital Pitié Salpetriere, hématologie APHP, Paris, France. 46Hôpital Emile Muller, Mulhouse, France. 47DRC, CHU, Poitiers, France. 48Hôpital Saint-Louis, Paris, France. 49Hematology, UMR U1236, University Hospital, Rennes, France. 50C.H.U. Henri Mondor, Créteil, France. 51Hématologie, CHU Hotel Dieu Université, Nantes, France. 52Hematology, Sorbonne University, Saint-Antoine Hôpital (AP-HP), UMRs 938, Paris, France. 53Hematology, University Hospital Inserm U-S1277 and CNRS UMR9020, Lille, France. 54These authors contributed equally: Xavier Leleu, Cyrille Hulin.

Belantamab Mafodotin, Pomalidomide,and Dexamethasone in Multiple Myeloma

Dimopoulos M, et al.
New England Journal of Medicine
June 2024
Authors and Affiliates
Meletios Athanasios Dimopoulos, M.D., Meral Beksac, M.D., Ludek Pour, M.D., Sosana Delimpasi, M.D., Vladimir Vorobyev, M.D., Hang Quach, M.D., Ivan Spicka, C.Sc., Jakub Radocha, M.D., Ph.D., Pawel Robak, M.D., Ph.D., Kihyun Kim, M.D., Michele Cavo, M.D., Kazuhito Suzuki, M.D., Ph.D., Kristin Morris, Pharm.D., Farrah Pompilus, Ph.D., Amy Phillips‑Jones, M.Sc., Xiaoou L. Zhou, M.D., Ph.D., Giulia Fulci, Ph.D., Neal Sule, M.B., B.S., M.D., Brandon E. Kremer, M.D., Ph.D., Joanna Opalinska, M.D., Ph.D., María‑Victoria Mateos, M.D., Ph.D., and Suzanne Trudel, M.D., for the DREAMM-8 Investigators Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens (M.A.D.), and General Hospital Evangelismos (S.D.) — both in Athens; the Department of Hematology, Ankara Liv Hospital, Istinye University, Ankara, Turkey (M.B.); the Department of Internal Medicine, Hematology, and Oncology, University Hospital Brno, Brno (L.P.), the First Faculty of Medicine, Charles University, and General Hospital, Prague (I.S.), and the Fourth Department of Internal Medicine–Hematology, University Hospital Hradec Králové, and Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové (J.R.) — all in the Czech Republic; Leningrad Regional Clinical Hospital, Saint Petersburg, Russia (V.V.); the University of Melbourne, St. Vincent’s Hospital, Melbourne, VIC, Australia (H.Q.); Medical University of Lodz, Łódź, Poland (P.R.); Sungkyunkwan University and Samsung Medical Center, Seoul, South Korea (K.K.); IRCCS Azienda Ospedaliero–Universitaria di Bologna, Seràgnoli Institute of Hematology, and Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy (M.C.); the Division of Clinical Oncology–Hematology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo (K.S.); GSK, Durham, NC (K.M.); GSK, Philadelphia (F.P.), and GSK, Collegeville (N.S., B.E.K., J.O.) — both in Pennsylvania; GSK, Stevenage, United Kingdom (A.P.-J.); GSK, Waltham, MA (X.L.Z., G.F.); the Hematology Department, Cancer Research Center–Instituto de Investigación Biomédica de Salamanca, University Hospital of Salamanca, Salamanca, Spain (M.-V.M.); and the Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto (S.T.)

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Hungria V, et al.
New England Journal of Medicine
June 2024
Authors and Affiliates
V. Hungria, P. Robak, M. Hus, V. Zherebtsova, C. Ward, P.J. Ho, A.C. Ribas de Almeida, R. Hajek, K. Kim, S. Grosicki, H. Sia, A. Bryant, M. Pitombeira de Lacerda, G. Aparecida Martinez, A.M. Sureda Balarí, I. Sandhu, C. Cerchione, P. Ganly, M. Dimopoulos, C. Fu, M. Garg, A.-O. Abdallah, A. Oriol, M.E. Gatt, M. Cavo, R. Rifkin, T. Fujisaki, M. Mielnik, N. Pirooz, A. McKeown, S. McNamara, X. Zhou, M. Nichols, E. Lewis, R. Rogers, H. Baig, L. Eccersley, S. Roy‑Ghanta, J. Opalinska, and M.-V. Mateos, for the DREAMM-7 Investigators Clinica São Germano (V.H.) and Hospital das Clínicas and Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo (G.A.M.), São Paulo, Centro de Pesquisa e Ensino em Saúde de Santa Catarin, Florianópolis (A.C.R.A.), and Universidade da Região de Joinville and Centro de Hematologia e Oncologia, Joinville (M.P.L.) — all in Brazil; Medical University of Lodz, Lodz (P.R.), Medical University of Lublin, Lublin (M.H., M.M.), and the Medical University of Silesia, Katowice (S.G.) — all in Poland; Gorodskaya Klinicheskaya Bol’nitsa Imeni Saint Petersburg Botkina, Moscow (V.Z.); the Royal North Shore Hospital (C.W.) and Liverpool Hospital (A.B.), Sydney, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and Pindara Private Hospital, Gold Coast, QLD (H.S.) — all in Australia; the Department of Hematooncology, University Hospital Ostrava, and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic (R.H.); Sungkyunkwan University and Samsung Medical Center, Seoul, South Korea (K.K.); Institut Català d’Oncologia–L’Hospitalet de Llobregat–Barcelona, Barcelona (A.M.S.B.), Institut Català d’Oncologia and Josep Carreras Research Institute, Hospital Germans Trias i Pujol, Badalona (A.O.), and Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cáncer, Ciberonc, Salamanca (M.-V.M.) — all in Spain; Cross Cancer Institute, Edmonton (I.S.), and GSK, Mississauga (H.B.) — both in Canada; the Hematology Unit, Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori,” IRST IRCCS, Meldola (C.C.), and IRCCS Azienda Ospedaliero–Universitaria di Bologna, Istituto di Ematologia “Seràgnoli,” Bologna (M.C.) — both in Italy; Christchurch Hospital, Christchurch, New Zealand (P.G.); National and Kapodistrian University of Athens, Athens (M.D.); the First Affiliated Hospital of Soochow University, Suzhou, China (C.F.); University Hospitals of Leicester NHS Trust, Leicester (M.G.), GSK, Stevenage (A.M., S.M.), and GSK, London (L.E.) — all in the United Kingdom; University of Kansas Cancer Center, Fairway (A.-O.A.); the Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel (M.E.G.); Rocky Mountain Cancer Centers–Denver–Midtown, Denver (R. Rifkin); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); GSK, Upper Providence, PA (N.P., X.Z., R. Rogers, S.R.-G., J.O.); and GSK, Durham (M.N.), and GSK, Research Triangle Park (E.L.) — both in North Carolina

Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma

Smith MR, et al.
Blood
May 2024
Authors and Affiliates
Mitchell R. Smith 1, Opeyemi A. Jegede 2, Peter Martin 3, Brian G. Till 4, Samir S. Parekh 5, David T. Yang 6, Eric D. Hsi 7, Thomas Witzig 7, Sandeep Dave 8, David Scott 9, Curtis Hanson 7, Lale Kostakoglu Shields 10, Nizar Abdel-Samad 11, Carla Casulo 12, Nancy L. Bartlett 13, Paolo F. Caimi 14, Tareq Al Baghdadi 15, Kristie A. Blum 16, Mark D. Romer 17, David J. Inwards 7, Rachel E. Lerner 18, Lynne I. Wagner 19, Richard F. Little 20 , Jonathan W. Friedberg 12, John P. Leonard 3, Brad S. Kahl 13 1. Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH*, 2. Dana Farber Cancer Institute, Boston, MA; 3. Meyer Cancer Center, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY; 4. Fred Hutchinson Cancer Center, Seattle, WA; 5. Mount Sinai, New York, NY; 6. University of Wisconsin Carbone Cancer Center, Madison, WI; 7. Mayo Clinic, Rochester, MN; 8. Duke University Medical Center, Durham, NC; 9. BCCA-Vancouver Cancer Centre, Vancouver, BC, Canada; 10. NYU-Langhorne Cancer Center, NY, NY; 11. The Moncton Hospital, Moncton, NB, Canada; 12. University of Rochester Medical Center-James P. Wilmot Cancer Center, Rochester, NY; 13. Washington University School of Medicine St. Louis and Siteman Cancer Center, St. Louis, MO; 14. Case Comprehensive Cancer Center, Cleveland, OH; 15. St. Joseph Mercy Hospital, Ann Arbor, MI ; 16. Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH; 17. Good Samaritan Hospital - Dayton, Kettering, OH; 18. Frauenshuh Cancer Center and Park Nicollet Institute, Minneapolis, MN; 19. University of North Carolina at Chapel Hill, Chapel Hill, NC; 20. Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD

Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant

Derman B, et al.
Blood Cancer Journal
May 2024
Authors and Affiliates
Benjamin A. Derman1, Jennifer Cooperrider1, Jacalyn Rosenblatt2, David E. Avigan2, Murtuza Rampurwala1, David Barnidge3, Ajay Major 4, Theodore Karrison5, Ken Jiang1, Aubrianna Ramsland1, Tadeusz Kubicki 1 and Andrzej J. Jakubowiak 1 1Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA. 2Beth Israel Deaconess Medical Center, Boston, MA, USA. 3The Binding Site Group, part of Thermo Fisher, Rochester, MN, USA. 4University of Colorado, Denver, CO, USA. 5Department of Public Health Sciences, University of Chicago, Chicago, IL, USA.

Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle celllymphoma: 2-year safety and efficacy analysis

Wang M, et al.
Blood Advances
May 2024
Authors and Affiliates
Michael Wang (The University of Texas M.D. Anderson Cancer Center, United States) Tadeusz Robak (Medical University of Lodz, Poland) Kami Maddocks (The Ohio State University, United States) Tycel Phillips (University of Michigan Comprehensive Cancer Center, United States) Stephen Smith (University of Washington/Seattle Cancer Care Alliance, United States) David Gallinson (Summit Medical Group, United States) Roser Calvo (AstraZeneca, United States) Chuan-Chuan Wun (AstraZeneca, United States) Veerendra Munugalavadla (AstraZeneca, United States) Wojciech Jurczak (Maria Sklodowska-Curie National Research Institute of Oncology, Poland)

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma

Touzeau C, et al.
Blood
May 2024
Authors and Affiliates
Cyrille Touzeau,1-3 Aurore Perrot,4 Cyrille Hulin,5 Salomon Manier,6 Margaret Macro,7 Marie-Lorraine Chretien,8 Lionel Karlin,9 Martine Escoffre,10 Caroline Jacquet,11 Mourad Tiab,12 Xavier Leleu,13 Herve Avet-Loiseau,4 Alexandra Jobert,14 Lucie Planche,14 Jill Corre,4 and Philippe Moreau1-3 1Service d’hématologie, Centre Hospitalier Universitaire (CHU) Hotel Dieu, Nantes, France; 2Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (CRCI2NA), INSERM, Centre National de la Recherche Scientifique (CNRS), Université d'Angers, Université de Nantes, Nantes, France; 3Site de Recherche Intégrée sur le Cancer (SIRIC) “Imaging and Longitudinal Investigations to Ameliorate Decision-making (ILIAD),” Institut National du Cancer-Direction Générale de l'Offre de Soins (INCA-DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM) 12558, Nantes-Angers, France; 4CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Université de Toulouse, Université Paul Sabatier (UPS), Service d’Hématologie, Toulouse, France; 5Service d’hématologie, Hopital Haut-Léveque, CHU de Bordeaux, Pessac, France; 6Maladies du Sang, CHRU de Lille, Lille, France; 7Service d’hématologie, CHU de Caen, Caen, France; 8Hématologie Clinique, CHU Dijon Bourgogne, Dijon, France; 9Hopital Lyon Sud, Pierre-Bénite, France; 10Service d’hématologie, CHU de Rennes, Rennes, France; 11Service d’hématologie, CHU de Nancy, Vandoeuvre-le` s-Nancy, France; 12Service d’hématologie, Centre Hospitalier Departemental, La Roche sur Yon, France; 13Service d’hématologie, CHU de Poitiers, Poitiers, France; and 14Département de recherche clinique, CHU Hotel Dieu, Nantes, France

French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry

Ferment B, et al.
British Journal of Haematology
May 2024
Authors and Affiliates
B. Ferment1,2 J. Lambert3 D. Caillot4,5 I. Lafon4 L. Karlin6 A. Lazareth6 C. Touzeau7 X. Leleu8 N. Moya8 S. Harel1,2 A. Perrot9 P. Bories9 L. Vincent10 S. Lamure11 M. Mohty12 F. Malard12 S. Manier13 I. Yakoub-Agha13 J.-M. Schiano De Colella14 G. Brisou14 A. Talbot1,2 O. Decaux15 R. Houot15 S. Le Gouill16,17 N. Bigot3 T. Facon13 J. Corre9 P. Moreau7 B. Arnulf1,2 1Department of Immuno-Hematology, Hôpital Saint Louis, APHP/Université Paris Cité, Paris, France 2Inserm U976 HIPI, Team 5: Lymphocyte Development and Lymphoid Disorders, Hôpital Saint Louis, Paris, France 3Biostatistics Department, Hôpital Saint Louis, APHP/Université Paris Cité, Paris, France 4Department of Hematology, Institut de Cancérologie de Bourgogne (ICB), Dijon, France 5Department of Hematology, Dijon University Hospital, Dijon, France 6Department of Hematology, Hospices Civils de Lyon, Lyon Sud University Hospital, Pierre-Benite, France 7Department of Hematology, Nantes University Hospital, Nantes, France 8Department of Oncology-Haematology and Cellular Therapy, Poitiers University Hospital, Poitiers, France 9Department of Hematology, IUCT Oncopole—Institut Universitaire du Cancer de Toulouse, Toulouse, France 10Department of Hematology, Montpellier University Hospital, Montpellier, France 11Department of Hematology, Centre Léon Bérard, Lyon, France 12Saint-Antoine Hospital, INSERM UMRs 938, Sorbonne University, Paris, France 13Department of Hematology, Lille Regional and University Hospital, Lille, France 14Department of Hematology, Institut Paoli Calmettes, Marseille, France 15Department of Hematology, Rennes University Hospital, Pontchaillou Hospital, Rennes, France 16Université Versailles Saint-Quentin, Versailles, France 17Department of Hematology, Institut Curie, Paris, France
Previous Next